eligibility_summary
Eligible: Pathologically confirmed DLBCL (NOS, THRLBCL, EBV+), grade 3b FL with DLBCL and recurrence, or transformed low-grade lymphoma (FL/MZL/CLL) to DLBCL with recurrence, judged likely to benefit from tafasitamab. Exclude: allergy to regimen drugs, unwilling to use contraception, uncontrolled diseases (e.g., diabetes, major organ failure), hematologic/endocrine disorders or other cancers, severe mental illness, investigator deems unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Real-world observational study in R/R DLBCL assessing tafasitamab + lenalidomide–based regimens, sometimes adding BTK inhibitors or chemotherapy/ADCs, some patients proceed to CAR T or transplant. Drugs/interventions and mechanisms: • Tafasitamab: Fc‑engineered anti‑CD19 IgG1 monoclonal antibody, targets CD19 on malignant B cells, induces ADCC/ADCP and direct apoptosis. • Lenalidomide: immunomodulatory drug (IMiD), binds cereblon to degrade Ikaros/Aiolos, boosting T‑ and NK‑cell activity, anti‑angiogenesis, and tumor cytotoxicity. • BTK inhibitors (small molecules): block BTK to inhibit B‑cell receptor signaling and downstream NF‑κB survival pathways. • ADC/chemotherapy: cytotoxic delivery to B‑cell antigens. • CAR T (cell therapy) or transplant used sequentially. Targeted cells/pathways: CD19+ B cells, BCR/BTK signaling, innate (NK/macrophage) and adaptive (T‑cell) immune activation.